Millions of adults take medications to help relieve symptoms of overactive bladder and reduce episodes of urinary incontinence. But research linking some of those medications called anticholinergic drugs, such as oxybutynin, to memory loss drove recommendations to treat urinary incontinence with beta-3 agonists, drugs that offer the same benefit but without the risk of cognitive decline. A new study in JAMA Network Open led by Northwestern Medicine and Duke University School of Medicine shows Black patients are less likely to fill prescriptions for newer, safer urinary incontinence drugs compared to white patients, potentially raising their risk for dementia. Read more.
Source: Duke University School of Medicine, June 12, 2023